No manipulation, but I wouldn't read too much into the lack of director buying either. The directors are getting half their salaries in shares anyway at the moment.
The share price does seem to have bottomed. I reckon that when Q3 figures come out later this month, the Q4 cash burn pre income will surprise the market. Remember also that all the product engineering work they've done for AZ is there for a reason too - the launch of Symbicort smart inhalers.
Once they've established greater financial stability and better prospects, a trade buyer will come along. IMO.
ADR Price at posting:
3.0¢ Sentiment: Buy Disclosure: Held
